Recruiting
Phase 2
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
About this study
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
- Condition
- Preclinical Alzheimer's Disease
- Tested
- Obicetrapib 10 mg, Matching placebo tablets
- Sponsor
- NewAmsterdam Pharma
Who can join
- Age
- 55 to 85 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 4
- Minimum age: 55 years
- Maximum age: 85 years
- Study condition: Preclinical Alzheimer's Disease
- participants with preclinical AD
Exclusion 1
- APOE genotype not meeting protocol-defined eligibility criteria
Where
1 site, 1 recruiting
K2 Medical Research
Nashville, Tennessee, United States
Potential match only. Final eligibility is determined by the study team.